The Covid-19 vaccine by Sinovac Biotech is not able to produce adequate antibodies to neutralise the highly mutated coronavirus strain Omicron, according to new research from the University of Hong Kong.
Both the Sinovac vaccine and another by Pfizer-BioNTech produced “inadequate” antibody responses to the variant, scientists said in a statement Tuesday night.
Of 25 people who received a full course of CoronaVac, none were found to have detectable levels of virus-fighting antibodies, according to study author and top infectious disease expert Yuen Kwok-yung and his team.
